VarmX, a Leiden, Netherlands-based biotech company focusing on the development of approaches for the reversal of anticoagulation, raised €30M in Series B2 funding.
The round was led by Sound Bioventures whilst the European Innovation Council (EIC) Fund also joined as a new investor. Backers included existing investors EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures (BGV), InnovationQuarter (IQ) and Libertatis Ergo Holding (LEH).
The company intends to use the funds to obtain investigational new drug (IND) approval for its lead compound VMX-C001 and to complete preparations for the pivotal clinical trial, including large scale manufacturing.
Founded in 2016 by Professor Pieter Reitsma as a spin-off from the Leiden University Medical Center (LUMC), and led by Dr. Jan Öhrström, CEO, VarmX is advancing its lead compound called VMX-C001, a modified recombinant blood factor X being developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy.
FinSMEs
25/05/2023